Trials / Withdrawn
WithdrawnNCT02626663
The Role of Microparticles as a Biomarker
The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.
Conditions
- Atypical Hemolytic Uremic Syndrome
- Thrombotic Thrombocytopenic Purpura
- Microparticles
- Microangiopathic Hemolytic Anemia
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2020-12-01
- Completion
- 2022-12-01
- First posted
- 2015-12-10
- Last updated
- 2019-02-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02626663. Inclusion in this directory is not an endorsement.